Regulatory lymphocytes: the dice that resolve the tumor endgame
Appl. cancer res
; 40: 1-9, Oct. 19, 2020. ilus
Article
de En
| LILACS, Inca
| ID: biblio-1281364
Bibliothèque responsable:
BR30.1
Localisation: BR30.1
ABSTRACT
A large number of cancer patients relapse after chemotherapeutic treatment. The immune system is capable of identifying and destroying cancer cells, so recent studies have highlighted the growing importance of using combinatorial chemotherapy and immunotherapy. However, many patients have innate or acquired resistance to immunotherapies. Long-term follow-up in a pooled meta-analysis exhibited long-term survival in approximately 20% of patients treated with immune checkpoint inhibitors or the adoptive transfer of chimeric T cells. It has been reported that high levels of immunoregulatory cells in cancer patients contribute to immunotherapy resistance via immunosuppression. Among the most important regulatory cell subtypes are the CD4+ T-regulatory cells (Tregs), identified by their expression of the well-characterized, lineage-specific transcription factor FOXP3. In addition to CD4+ Tregs, other regulatory cells present in the tumor microenvironment, namely CD8+ Tregs and IL10-producing B-regulatory cells (Bregs) that also modulate the immune response in solid and lymphoid tumors. These cells together have detrimental effects on tumor immune surveillance and anti-tumor immunity. Therefore, targeting these regulatory lymphocytes will be crucial in improving treatment outcomes for immunotherapy.
Mots clés
Texte intégral:
1
Indice:
LILACS
Sujet Principal:
Lymphocytes T régulateurs
/
Immunothérapie
/
Tumeurs
Type d'étude:
Prognostic_studies
langue:
En
Texte intégral:
Appl. cancer res
Thème du journal:
NEOPLASIAS
Année:
2020
Type:
Article